CNS Cluster Addiction Drug Development Pipeline Market Review, Analysis and Forecasts 2017


Posted May 18, 2017 by devpatel

The CNS Cluster Drug Addiction pipeline guide encapsulates all the dormant and discontinued pipeline projects. To Get Discount on Report @ Goo.gl/Reports .

 
CNS Cluster Addiction Drug Development Pipeline Market Review, Analysis and Forecasts 2017 Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with CNS Cluster Addiction Drug Development Pipeline in subject line and your contact details.
The Market Research Report on CNS Cluster Pipeline Drug Addiction development states the symptoms for Alcohol Addiction, Drug Addiction, Nicotine Addiction and Opium (Opioid) Addiction. The CNS Cluster Pipeline Drug Addiction report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for features dormant and discontinued projects.

Offers from 10th May 2017 to 2nd June 2017
• All reports priced >=1,000 – 20% Discount – Single User; 25% Discount – Global Site License.
• Buy 2 Reports Get 1 Report Free
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. There are a total of 67 products in development for this indication, by 38 companies and 16 academic institutions.
To Get Discount on Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1001381 .
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression and restlessness, inability to control drinking and violent behavior. There are a total of 38 products in development for this indication, by 29 companies and five academic institutions.
Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. There are a total of 19 products in development for this indication, by 13 companies and 5 academic institutions. The majority of companies are developing single pipeline program in this space, while Omeros are developing two.
Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). There are a total of 33 products in development for this indication, by 23 companies and three academic institutions.
Purchase the Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=1001381 .

Key Companies Operating in this Pipeline include:
Astraea Therapeutics, Addex therapeutics, The University of Kansas, Embera NeuroTherapeutics, InterveXion Therapeutics, Omeros, Opiant Pharmaceuticals and Orexigen Therapeutics, Abbvie, Astraea Therapeutics, Lochola Research and SK Biopharmaceuticals, Indivior, INSYS Therapeutics, Omeros, Pfizer and Zynerba Pharmaceuticals.

There is a substantial degree of overlap between these indications in terms of the types of molecular target which are being studied. The mu and kappa-opioid receptors are the dominant molecular target across alcohol, drug and opioid addiction, and other neurotransmitter receptors such as the cannabinoid and dopamine receptors are common molecular targets across the three. In contrast, while such neurotransmitter receptors are present in the nicotine addiction pipeline, the opioid receptors are not, and the dominant molecular target is the orexin receptor type 1.
Scope of the Report
• Which companies are the most active within the pipeline for addiction therapeutics?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in the field of addiction therapeutics?
Sample for the Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=1001381 .
List of Tables
Number of Products under Development for Alcohol Addiction
Number of Products under Development by Companies, Alcohol Addiction
Number of Products under Development by Universities/Institutes, Alcohol Addiction
Products under Development by Companies, Alcohol Addiction
Products under Development by Universities/Institutes, Alcohol Addiction
Number of Products under Development for Drug Addiction
Number of Products under Development by Companies, Drug Addiction
Number of Products under Development by Universities/Institutes, Drug Addiction
Products under Development by Companies, Drug Addiction
List of Figures
Number of Products under Development for Alcohol Addiction
Number of Products under Development by Companies, Alcohol Addiction
Number of Products under Development by Universities/Institutes, Alcohol Addiction
Number of Products under Development for Drug Addiction
Number of Products under Development by Companies, Drug Addiction
Number of Products under Development by Universities/Institutes, Drug Addiction
Number of Products under Development for Nicotine Addiction
Number of Products under Development by Companies, Nicotine Addiction
Number of Products under Development for Opium (Opioid) Addiction
Browse All Reports on Pharmaceuticals Market Research Reports.
About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By ReportsnReports.com
Country India
Categories Health
Tags drug addiction pipeline
Last Updated May 18, 2017